Asset Details
Do you wish to reserve the book?
Human oral pharmacokinetics of 4-hydroxy isoleucine and dosage simulation studies for predicting its pharmacodynamics in diabetes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Human oral pharmacokinetics of 4-hydroxy isoleucine and dosage simulation studies for predicting its pharmacodynamics in diabetes
Do you wish to request the book?
Human oral pharmacokinetics of 4-hydroxy isoleucine and dosage simulation studies for predicting its pharmacodynamics in diabetes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Human oral pharmacokinetics of 4-hydroxy isoleucine and dosage simulation studies for predicting its pharmacodynamics in diabetes
2025
Overview
INTRODUCTION:
4-hydroxy isoleucine (4-HIL), a potent glucose-lowering agent and insulin secretagogue, is widely available in nutraceutical market as fenugreek seed extract formulations. This study aims to elucidate the oral pharmacokinetics (PK) of 4-HIL in healthy human volunteers to standardize its dose and dosing regimen, ensuring its potential for effective diabetes management.
METHODOLOGY:
Twelve healthy volunteers received a single oral administration of 150 mg of 4-HIL as fenugreek seed extract tablets. Caplillary blood samples were collected at various time points within 24 h and plasma levels of 4-HIL were quantified using liquid chromatography-tandem mass spectrometry. In vitro studies on 4-HIL pharmacodynamics, derived from the literature, were used to calculate the half-minimal effective concentration (EC50). PK assessments based on compartmental modelling and dosage simulation studies were conducted using PKsolver and ModVizPOP, respectively. The PK simulation included three distinct dosage regimens (150 mg thrice daily, 225 mg twice daily, or 450 mg once daily) to evaluate EC50 level attainment.
RESULTS:
The best-fit was observed with a two-compartmental model, with maximum 4-HIL plasma concentration (Concentration maximum, 2.42 ± 0.61 µg/mL) observed at 0.5 h (Time maximum). The derived mean EC50 of 4-HIL, needed to reduce blood glucose, was 1.50 ± 0.31 µg/mL. The PK simulation study indicated that daily intake of 450 mg 4-HIL in all three tested dosing regimens had maintained EC50 levels more than 18 h for glucose-lowering effects.
CONCLUSION:
The optimal 4-HIL dose of 450 mg/day up to three divided dosing regimens has proven effective and hence may be considered for future diabetic trials.
Publisher
Wolters Kluwer - Medknow,Medknow Publications and Media Pvt. Ltd,Medknow Publications & Media Pvt. Ltd
Subject
/ Adult
/ Diabetes
/ Diabetes Mellitus - drug therapy
/ Dose-Response Relationship, Drug
/ Female
/ Glucose
/ Humans
/ Hypoglycemic Agents - administration & dosage
/ Hypoglycemic Agents - pharmacokinetics
/ Isoleucine - administration & dosage
/ Isoleucine - analogs & derivatives
/ Isoleucine - pharmacokinetics
/ Male
/ Plant Extracts - administration & dosage
